Clinical Genomic Interpretation, Bioinformatics and AI Markets 2027–2031

Clinical Genomic Interpretation, Bioinformatics and AI Markets: Market Forecast, Competitive Landscape, Company Revenue Estimates, Technology and World Metropolitan Area Market Sizes, 2027–2031

Global forecasts of clinical genomic interpretation, bioinformatics and AI revenue by product, technology, application, deployment and customer, for 14 countries and regions and 237 metropolitan areas, with 38 company profiles. Variant interpretation and clinical decision software, secondary analysis and pipelines, interpretation and curation services, genomic data platforms and cloud, and knowledge bases and content licences.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Every genomic test ends with an interpretation. The software, data and services that turn raw sequence reads into a signed clinical report grow far faster than sequencing itself, because test volumes rise, panels become exomes and genomes, and the costly step moves from the sequencer to the scientist reviewing variants. AI is joining that work, and interpretation is moving to the cloud. The market grows from $980.0 million in 2026 to $1,850.0 million in 2031, at 13.6% a year.

Market Size 2026: USD $980.0M Market Size 2031: USD $1,850.0M CAGR: 13.6%

Situation Analysis: what is really happening

• AI joins the interpretation. Generative AI & Large Language Models are the fastest-growing line at 42.6% a year, from 4.0% to 12.5% of the market, and Machine Learning Classifiers grow 17.6%, while Rules-Based & Curated Knowledge remains the foundation at 39.5% of the market in 2031.
• Interpretation moves to the cloud. Cloud / SaaS grows 17.4% a year, from 44.0% to 52.0% of the market, while On-Premise & Instrument-Embedded software grows 5.8% and falls from 27.0% to 19.0%.
• Interpretation software leads. Variant Interpretation & Clinical Decision Software is the largest product line, rising from 34.0% to 36.0% of the market, and Genomic Data Platforms & Cloud is the fastest-growing at 15.8%, while Secondary Analysis & Pipelines grows 10.2% as analysis is bundled with sequencers or given away.
• Oncology is the core. Oncology & Tumour Profiling is 47.0% of the market in 2026, and Pharmacogenomics is the fastest-growing application at 15.4% a year.
• Hospitals bring interpretation in house. Hospital & Health System Labs grow 14.9% a year to 35.0% of the market, while Reference & Commercial Genomic Labs grow 11.3% as the largest laboratories build their own tools.
• New owners and new tools. EQT agreed a business combination with QIAGEN, Illumina launched its BioInsight platform and DRAGEN Ultra, GeneDx acquired Fabric Genomics, SeqOne agreed to acquire Congenica, and BGI-Research and Zhejiang Lab open-sourced the Genos genomic foundation model. China is the fastest-growing country, at $70.3 million in 2026 and 20.7% a year.

Company Analysis: who is positioned, who is exposed

• Agilent Technologies, Bio-Rad Laboratories, Illumina, MGI Tech / BGI Group, Oxford Nanopore Technologies, QIAGEN (QIAGEN Digital Insights), Roche and Thermo Fisher Scientific: Sequencing, PCR and diagnostics companies, with HSR’s estimates of in-scope revenue and ranges.
• 3billion, Euformatics, Fabric Genomics (GeneDx), Genomenon, Golden Helix, Limbus Medical Technologies (varvis), NGeneBio, PhenoTips, Saphetor (VarSome), SeqOne, SOPHiA GENETICS, Strand Life Sciences and Velsera: Interpretation software and service specialists.
• GenXys Health Care Systems, InformedDNA (Coriell Life Sciences) and Translational Software: Pharmacogenomic decision support.
• Amazon Web Services, BC Platforms, DNAnexus, Google Cloud, Lifebit, Microsoft and NVIDIA: Genomic data platforms, cloud and acceleration.
• Allelica, Caris Life Sciences, Genomics and Tempus AI: Clinico-genomic data and polygenic risk.
• bioMérieux, One Codex and Ridom (Bruker): Infectious disease and microbial genomics software.

In all, 38 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Inside the report: HSR’s revenue estimate for every named company, with low–high ranges, and a growth and share-change map of every product and deployment line. Names and values are in the full report.

Questions this report answers

• How large is the clinical genomic interpretation, bioinformatics and AI market, and how fast will it grow?
• How much in-scope revenue do Illumina, SOPHiA GENETICS, QIAGEN, Tempus, Velsera and other suppliers earn?
• How fast are machine learning and generative AI changing variant interpretation, and what does open-source AI mean for prices?
• How quickly is interpretation moving to the cloud, and which applications grow fastest?
• What do FDA, EU IVDR and AI Act, GDPR and China data rules mean for suppliers?
• How large is each country market, and which metropolitan areas lead?

What's inside

• 418 pages, 23 chapters, 131 tables and 59 figures
• Forecasts for 2027–2031 from a 2026 base year, by product, technology, application, deployment and customer, for 14 countries and regions
• Market sizes for 237 world metropolitan areas in 2026 and 2031, with the top 30 and fastest-growing metros
• How clinical genomic interpretation works; products, technologies, applications, deployment models and customers; technology trends; IVD – The Big Picture
• Regulation, data and quality; 10 market-moving developments; competitive landscape with company revenue estimates, SWOT, Porter's Five Forces and strategic recommendations
• 38 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Genomic software and AI companies: size target segments by product, technology, application and deployment, and benchmark competitors.
• Sequencing and diagnostics companies: plan informatics, AI and partnership strategies.
• Clinical laboratories and health systems: plan build-versus-buy and the move to the cloud.
• Investors: assess consolidation, new owners and growth.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.